Long-term prognosis and its associated predictive factors in patients with eosinophilic gastroenteritis

Table 1 Clinical characteristics of eosinophilic gastroenteritis patients in this cohort, n (%)

All patients (N = 55)
Demographic characteristics		Complications		ESR (mm/h)2	4.00 [2.00, 8.00]
Sex, female	31 (56.4)	Ascite	17 (30.9)	Elevated ESR (> 15)	7 (7/49, 14.3)
Age (yr)2	38.00 [25.50, 50.00]	Intestinal obstruction	8 (14.5)	CRP (mg/L)2	1.62 [0.84, 4.38]
BMI (kg/m2)1	23.28 ± 3.96	Comorbidities		Elevated hsCRP (> 3)	11 (11/53, 20.8)
BMI > 24	21 (38.9)	Hp infection	16 (16/50, 32.0)	ANA (+)	8 (8/47, 17.0)
Clinical manifestations		HTN	8 (14.5)	ANCA (+)	4 (4/46, 8.7)
Disease duration (mo)2	5.00 [1.00, 30.00]	DM	3 (5.5)	Allergen test (+)	14 (14/28, 50.0)
Allergic history	18 (32.7)	HBV infection	4 (7.3)	Inhalant allergen	8 (8/25, 32.0)
Allergic rhinitis	10 (18.2)	Klein classification		Food allergen	8 (8/27, 29.6)
Asthma	11 (20.0)	Mucosal type	28 (50.9)	Endoscopy findings
Urticaria	2 (3.6)	Muscular type	9 (16.4)	Duodenum involvement	40 (40/54, 74.1)
Symptoms, n (%)		Serosal type	18 (32.7)	Bulb	27 (27/54, 50.0)
Abdominal pain	49 (89.1)	Laboratory tests		Post-bulb	16 (16/54, 29.6)
Diarrhea	34 (61.8)	EOS (× 109/L)2	1.16 [0.67, 3.91]	Descending part	29 (29/54, 55.6)
Nausea	29 (52.7)	Hb (g/L)1	138.36 ± 14.81	Hyperaemia	31 (31/54, 57.4)
Vomiting	26 (47.3)	PLT (× 109/L)1	279.29 ± 81.84	Erosion	13 (13/54, 24.1)
Distension	27 (49.1)	Alb (g/L)2	40.00 [37.00, 42.00]	Ulcer	5 (5/54, 9.3)
GI bleeding	3 (5.5)	IgE (KU/L)2	152.00 [66.55, 335.50]	Therapy
Weight loss	36 (65.5)	> 60	38 (79.2)	Diet therapy	7 (12.7)
Fever	4 (7.3)	> 300	13 (27.1)	Anti-allergic agents	7 (12.7)
Rash	6 (10.9)			Immunosuppressors	3 (5.5)

¹mean ± SD.

²Mean[Q1, Q3].

EGE: Eosinophilic gastroenteritis; BMI: Body mass index; GI: Bleeding: gastrointestinal bleeding; Hp: Helicobacter pylori; HTN: Hypertension; DM: Diabetes mellitus; HBV: Hepatitis B virus; EOS: Eosinophil count; Hb: Hemoglobin; PLT: Platelet; T-IgE: Total serum immunoglobin E; hsCRP: High sensitivity C reactive protein; ESR: Erythrocyte sedimentation rate; ANA: Antinuclear autoantibodies; ANCA: Anti-neutrophil cytoplasmic antibodies.